Newsfeeds - Spark Newswire

3 minute read

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

By Vandana Singh

Today, 12:28 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ADCT

1 minute read

ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug

By Vandana Singh

Today, 12:28 PM

ADC Therapeutics SA (NYSE:ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC:BIOVF) for the development and commercialization of…

ADCT

2 minute read

ADC Therapeutics Announced Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA in Europe and Select International Territories; ADC Therapeutics is Eligible to Receive Up to $435M, Including Milestones

By Charles Gross

Today, 12:28 PM

ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.

ADCT

1 minute read

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

By Vandana Singh

Today, 12:28 PM

ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301)…

ADCT

8 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 12:28 PM

On Tuesday, 123 stocks made new 52-week lows.

ACLX

1 minute read

Analyst Ratings

Analyst Ratings for ADC Therapeutics

By Benzinga Insights

Today, 12:28 PM

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:

ADCT

1 minute read

Analyst Ratings

RBC Capital Maintains Outperform Rating for ADC Therapeutics: Here’s What You Need To Know

By Benzinga Insights

Today, 12:28 PM

RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the last 24 hours, at $7.71 per share.

ADCT